

Attorney Docket No: 23546-07724US

Client Ref: RTS-0333

USSN: 10/008,789

**AMENDMENTS TO THE CLAIMS**

1. (Amended herein): A compound 8 to 50 nucleobases in length targeted to ~~a~~ the 5'-untranslated region, a ~~the~~ start codon region, a ~~the~~ coding region, or ~~a~~ the 3'-untranslated region of a nucleic acid molecule of SEO ID NO:3 encoding thyroid hormone receptor interactor 6 wherein said compound specifically hybridizes with one of said regions and inhibits the expression of thyroid hormone receptor interactor 6.

2. (original): The compound of claim 1 which is an antisense oligonucleotide.

3. (previously canceled)

4. (original): The compound of claim 2, wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

5. (original): The compound of claim 4, wherein the modified internucleoside linkage is a phosphorothioate linkage.

6. (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

7. (original): The compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

8. (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

9. (original): The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.

10. (original): The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

11. (previously canceled)

12. (original): A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

13. (original): The composition of claim 12 further comprising a colloidal dispersion system.

Attorney Docket No: 23546-07724US  
Client Ref: RTS-0333  
USSN: 10/008,789

14. (original): The composition of claim 12 wherein the compound is an antisense oligonucleotide.

15. (previously amended): A method of inhibiting the expression of thyroid hormone receptor interactor 6 in cells or tissues comprising contacting said cells or tissues *in vitro* with the antisense compound of claim 1 so that expression of thyroid hormone receptor interactor 6 is inhibited.

16-18. (previously canceled)

19. (original): The compound of claim 1 targeted to a nucleic acid molecule encoding thyroid hormone receptor interactor 6, wherein said compound specifically hybridizes with and differentially inhibits the expression of one or more of the variants of thyroid hormone receptor interactor 6 relative to the remaining variants of thyroid hormone receptor interactor 6.

20. (Amended herein): The compound of claim 19 targeted to a nucleic acid molecule encoding thyroid hormone receptor interactor 6, wherein said compound hybridizes with and specifically inhibits the expression of TRIP6-I (SEQ ID NO:3).

21. (Reinstated - formerly claim # 3): The compound of claim 2 wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO: 13, 14, 16, 17, 18, 19, 22, 23, 25, 26, 27, 29, 30, 31, 33, 35, 40, 41, 43, 45, 46, 47, 48, 49, 51, 53, 54, 55, 56, 57, 59, 60, 61, 64, 65, 66, 67, 68, 69, 70, 71, 72, 74, 76, 78, 81, 84, 87 or 88.

22. (New): The compound of claim 21, wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO:22.